Critical Analysis: Cardio Diagnostics (CDIO) and Its Competitors

Cardio Diagnostics (NASDAQ:CDIO) is one of 844 public companies in the “Biotechnology” industry, but how does it contrast to its peers? We will compare Cardio Diagnostics to similar companies based on the strength of its earnings, analyst recommendations, risk, institutional ownership, dividends, profitability and valuation.

Earnings and Valuation

This table compares Cardio Diagnostics and its peers revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Cardio Diagnostics	$14,450.00	-$6.50 million	-0.55
Cardio Diagnostics Competitors	$734.37 million	$13.62 million	-10.01

Cardio Diagnostics’ peers have higher revenue and earnings than Cardio Diagnostics. Cardio Diagnostics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a breakdown of current recommendations for Cardio Diagnostics and its peers, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardio Diagnostics	1	0	0	0	1.00
Cardio Diagnostics Competitors	9782	15048	45279	1571	2.54

As a group, “Biotechnology” companies have a potential upside of 99.66%. Given Cardio Diagnostics’ peers stronger consensus rating and higher probable upside, analysts plainly believe Cardio Diagnostics has less favorable growth aspects than its peers.

Profitability

This table compares Cardio Diagnostics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cardio Diagnostics	-43,133.33%	-82.28%	-76.03%
Cardio Diagnostics Competitors	-9,054.47%	-198.89%	-30.64%

Insider & Institutional Ownership

8.1% of Cardio Diagnostics shares are owned by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are owned by institutional investors. 9.0% of Cardio Diagnostics shares are owned by insiders. Comparatively, 12.9% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Cardio Diagnostics has a beta of 2.32, indicating that its share price is 132% more volatile than the S&P 500. Comparatively, Cardio Diagnostics’ peers have a beta of 1.11, indicating that their average share price is 11% more volatile than the S&P 500.

Summary

Cardio Diagnostics peers beat Cardio Diagnostics on 10 of the 13 factors compared.

About Cardio Diagnostics

Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.